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Background: Most patients with small cell lung cancer (SCLC) or neuroblastoma (NB) already show clinically
detectable metastases at diagnosis and have an extremely poor prognosis even when treated with combined
modalities. The HuD-antigen is a neuronal RNA-binding protein that is expressed in 100% of SCLC tumor cells and
over 50% of neuroblastoma cells. The correlation between high titers of circulating anti-HuD antibodies in patients
and spontaneous tumor remission suggests that the HuD-antigen might be a potential molecular target for
immunotherapy.
Methods: We have constructed a new antibody-toxin compound (called BW-2) by assembling a mouse
anti-human-HuD monoclonal antibody onto streptavidin/saporin complexes.
Results: We found that the immunotoxin BW-2 specifically killed HuD-positive human SCLC and NB cancer cells
at very low concentrations in vitro. Moreover, intratumoral immunotoxin therapy in a nude mouse model of
human SCLC (n = 6) significantly reduced local tumor progression without causing toxicity. When the same
intratumoral immunotoxin protocol was applied to an immunocompetent A/J mouse model of NB, significant
inhibition of local tumor growth was also observed. In neuroblastoma allografted A/J mice (n = 5) treated twice
with intratumoral immunotoxin, significant tumor regression occurred in over 80% of the animals and their
duration of tumor response was significantly prolonged.
Conclusions: Our study suggests that anti-HuD based immunotoxin therapy may prove to be an effective
alternative treatment for patients with SCLC and NB.Background
Both small cell lung cancer (SCLC) and neuroblastoma
(NB) express high-levels of HuD protein. HuD is a 40
kD neuronal RNA-binding protein that is expressed in
100% of SCLC tumor cells and at least 50% of NB cells
[1]. Most patients with SCLC or NB have disseminated
disease at the time of diagnosis and the prognosis is usu-
ally poor despite aggressive multimodality treatment.
New and effective therapies are needed to improve
disease outcome in these patients. High polyclonal
anti-HuD antibody titers are associated with occa-
sional spontaneous remission in some SCLC patients,
suggesting that the HuD-antigen might be a good* Correspondence: yuan_rui@hotmail.com
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unless otherwise stated.molecular target for specific immunotherapy against
HuD positive tumors [2].
Immunotoxins are unique proteins made by conjugating
toxins to antigen specific antibodies that are designed to
kill a targeted cell population [3]. Saporin, a ribosomal
toxin, is a plant enzyme that irreversibly blocks protein
synthesis. Antibodies conjugated to saporin have been
employed for leukemia treatment and for pain control in
neurologic disorders [4,5]. The majority of immunotoxins
developed for cancer treatment have targeted leukemia
and are administered intravenously [5,6]. Multiple doses
are often required to achieve a therapeutic effect. Clinical
success of systemic immunotoxin therapy in solid tumors
has been largely unimpressive because of poor immuno-
toxin penetration into the tumor and due to toxin side
effects, such as vascular leak syndrome [7]. Little is known
regarding the efficacy of intratumoral (i.t.) immunotoxin
therapy on solid tumors.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pound (BW-2), which is constructed by attaching a bio-
tinylated anti-HuD monoclonal antibody (mAb) onto a
streptavidin-saporin complex. We found that this immu-
notoxin aggressively killed HuD-positive SCLC and NB
cells in vitro with high specificity. Intratumoral injection
of the immunotoxin greatly inhibited tumor progression
without inducing toxicity in a nude mouse model of
human SCLC. Furthermore, intratumoral immunotoxin
induced significant tumor regression in 80% of immuno-
competent neuroblastoma allografted A/J mice and sig-
nificantly prolonged duration of tumor response. This
new compound may offer a therapeutic option with sig-
nificant potential for patients with tumors that express
the HuD protein.
Results
SCLC and neuroblastoma cell line HuD-protein detection
by anti-HuD mAb
To assure that mouse mAb 16A11 was specific for HuD-
antigen in both human and mouse HuD-positive cancer
cells, we first tested the reactivity of the antibody to cell ex-
tracts obtained from SCLC, neuroblastoma, and extracts
those extracted from leukemia and mouse T lymphoma
control cell lines by Western blot. Figure 1 shows that hu-
man SCLC (NCI-H69, DMS79) and mouse neuroblastoma
neuro-2a cell extracts strongly express HuD (~39-40 kD)
whereas control cell lines (BW5147 and K562) failed toFigure 1 Western blot analysis of HuD proteins in SCLC,
neuroblastoma, and leukemia/lymphoma cell lines. Protein
extracts from cell lysates were subjected to SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) on a NuPAGE™ 4-12% Bis-Tris gel,
transferred to nitrocellulose membrane. The membrane was probed
with anti-HuD mAb (16A11) and a HRP-conjugated goat anti-mouse
IgG detection system. The neuroblastoma (Neuro-2a) and SCLC
(NCI-H69, DSM79) extracts demonstrated strong bands at 40 kD, whereas
two control cell line (BW5147, K562) extracts were devoid of signal.express HuD antigen at the expected molecular weight. All
cell lines displayed faint nonspecific binding at ~64 kD, but
lymphoma control cell line BW5147 showed stronger
signal compared to all other cell lines.
BW-2 immunotoxin specifically kills Hu-D positive tumor
cells
The killing effect of BW-2 was quantified in HuD-
positive NCI-H69, Neuro-2a, and HuD-negative K562
tumor cell lines. Figure 2 shows that the BW-2 construct
killed the targeted NCI-H69 SCLC (Figure 2A) and
neuro-2a (Figure 2B) cells with great potency (ED50 <
0.5 μg/ml). In contrast, the saporin-streptavidin complex
alone or mAb alone exhibited limited non-specific kill-
ing only at much higher concentrations (P < 0.05). The
addition of non-biotinylated mAb at a 20-fold excess
only partially blocked cell killing by BW-2. Adding either
streptavidin or biotin alone to NCI-H69 or neuro-2a cell
cultures failed to block cell killing induced by BW-2.
Minimal non-specific cytotoxicity was induced in HuD-
negative control cells, but again only at much higher
concentrations of BW-2 (2–5 μg/ml) (Figure 2A).
Trypan blue staining for cell death detection as well as
the Cell Titer 96 Proliferation Assay were utilized to
confirm cell viability and all tests showed similar results
(data not shown).
Anti-HuD immunotoxin inhibits tumor growth and
prolongs duration of tumor response in tumor
xenografted mice
Nude mouse models of human SCLC have been used ex-
tensively by many investigators [8,9] and tumor xenografts
in the nude mouse usually develop within 2 weeks after
subcutaneous inoculation of NCI-H69 cancer cells. In our
experiments, the tumor mass expanded to 300-500 mm3
over 2–3 weeks after s.c. implantation of 1 × 107 viable
tumor cells into the flanks of nude mice. Tumor-grafted
mice were capable of surviving for 6–8 weeks before they
were overwhelmed by the tumor burden (Figure 3A). In
contrast to common belief, we found that after s.c. tumor
implantation, significant tumor metastasis developed in
multiple organs (lung, liver, and bone marrow) after the
local tumor reached 1000–1500 mm3 and the metasta-
sized cancer cells were easily detected by immunoreaction
with biotinylated anti-HuD mAb and Cy3 fluorescent
detection (Figure 3B).
To determine whether intratumoral BW-2 affected
tumor growth, the tumor xenografted nude mice were
treated once with immunotoxin (BW-2 at 1 mg/kg)
injected directly into the s.c. tumor. Control tumor
xenografted mice received equivalent subcutaneous in-
jections of pure anti-HuD mAb alone, saporin toxin
alone, or sham treatment with saline. The tumor shrink-
ing effect of immunotoxin treatment was clearly visible
Figure 2 Immunotoxin BW-2 efficiently kills SCLC and neuroblastoma cancer cells. BW-2 kills (A) HuD-positive H69 cells and (B) neuro-2a,
whereas no cytotoxicity occurred in the control (C) HuD-negative K562 cells. Log dilutions of BW-2 (0–5 μg/ml) were added to the cell culture
wells (5 × 104 cells/well) and incubated at 37°C for 72 hr. Exposure to equal molar concentrations of streptavidin-saporin (Streptavidin-SP) alone
or mAb (16A11) alone served as controls. BW-2 efficiently killed the targeted H69 and neuro-2a cancer cells with great potency (P < 0.005).
SAP-streptavidin alone or 16A11 mAb alone induced only mild non-specific killing at higher concentrations. Data represents the mean of three
tests in a single representative experiment repeated 3 times.
Ehrlich et al. Journal of Hematology & Oncology 2014, 7:91 Page 3 of 8
http://www.jhoonline.org/content/7/1/91as control mice continued to demonstrate rapid tumor
volume expansion whereas the primary tumors in the
BW-2 treated animals remained static or actually
regressed for ~3 weeks (Figure 4A/B). The residual
tumor eventually re-grew into a larger mass 6–9 weeks
after one time local immunotoxin treatment.
We hypothesized that intratumoral immunotoxin ther-
apy for SCLC or NB might be more effective in immu-
nocompetent mice because the immunotoxin-induced
tumor cell death would release abundant tumor antigens,
which could potentially activate infiltrating immune cellsFigure 3 Nude mouse model of human SCLC and pathology. Viable H
the flank of nude mice. (A) Subcutaneous tumor nodules developed and p
metastases occurred when the s.c. tumor reached a certain size (~1000 mm
immunoreaction with biotinylated anti-HuD mAb and Cy3 fluorescent detelocally to kill residual tumor cells and prevent distant
metastasis. Because a mouse model of SCLC in immuno-
competent mice is not available, the mouse model of
HuD-positive neuro-2a NB in immunocompetent A/J
mice was used for this study. The neuro-2a cell is a sub-
clone of a murine neuroblastoma that was harvested from
a spontaneously developed tumor in A/J mice. The neuro-
2a implanted A/J mouse model has been used previously
for studying efficacy of DNA vaccines [10]. As shown in
Figure 5, more marked efficacy of BW-2 was observed in
neuro-2a tumor allografted immunocompetent A/J mice.69 SCLC cells (1x107/100 μl PBS) were subcutaneously implanted into
rogressed rapidly after s.c. implantation and multiple organ cancer
3). (B) The metastasized cancer cells were easily detected by
ction.
Figure 4 Intratumorally injected immunotoxin BW-2 inhibits growth in HuD-positive H69 SCLC tumor xenografted mice. SCLC tumor
xenografted nude mice (n = 6) were treated with one time intratumoral immunotoxin, or an equivalent dose of mAb alone, saporin toxin alone,
or saline. A) Tumor size in BW-2 treated mice remained static or actually regressed for ~3 weeks. B) The control mice exhibited rapidly progressive
increases in tumor volume and were overwhelmed by large tumor burden as well as metastases.
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served at the injection site. Fur began to grow back within
a few weeks after the final treatment. Otherwise, no other
adverse effects were detected. Long-term follow-up over
7 weeks showed no local tumor relapse or distant metasta-
sis in 80% of the BW-2 treated immunocompetent A/J
mice. In contrast, the sham treated control mice had over-
whelming local tumor growth. Additionally, multiple or-
gans (brain, lung, liver, adrenal gland and bone marrow)
had clearly detectable tumor metastases when exam-
ined either by direct tissue examination (Figure 5) or by
immunohistochemistry.
Discussion
SCLC and NB are both neoplasms of neuroendocrine
origin. Reports of a strong correlation between the pres-
ence of anti-HuD antibodies and spontaneous remission
of SCLC in some patients suggest that the HuD-antigen
might be a specific molecular target for immunotherapy
[11,12]. In this study, we report that a new anti-HuD
immunotoxin, BW-2, effectively kills HuD-positive
SCLC and NB cells in vitro. When the immunotoxin
was injected directly into tumor sites, local tumorprogression was profoundly inhibited with no evidence
of significant toxicity detected in either tumor implanted
mouse model. In fact, more than 80% of BW-2 treated
neuro-2a allografted mice displayed significant tumor
regression, and as a result, the tumor response in BW-2
treated tumor xenografted mice was substantially pro-
longed compared to all other control groups.
Until now, the majority of immunotoxins developed
for cancer treatment have been used to target leukemia
and have been administered intravenously [5,6]. Based
on our in vitro studies, in which the anti-HuD mAb or
BW-2 immunotoxin were readily internalized into
HuD-positive cancer cells in cell culture, we hypothe-
sized that the BW-2 immunotoxin injected directly into
the tumor mass would readily recognize, enter and kill
the targeted antigen-specific tumor cell. We further
hypothesized that intratumoral (i.t.) immunotoxin therapy
would provoke far less systemic toxicity than systemic
immunotoxin therapy. In fact, one time intratumoral in-
jection of BW-2 in subcutaneously implanted SCLC nude
mice significantly inhibited local tumor growth for a 3–4
week period and prolonged duration of tumor response
compared to controls, confirming the in vivo effectiveness
Figure 5 Intratumorally injected BW-2 inhibits tumor growth and prolongs survival in HuD-positive neuroblastoma allografted mice.
A) Two weekly doses of intratumoral BW-2 treatment in neuro-2a allografted A/J mice (n = 5) significantly inhibited local tumor growth as
compared to PBS treated controls. In BW-2 treated mice, a temporary loss of fur was observed at the injection site while significant local tumor
growth was observed in control mice. Major organs in perfused animals were checked for evidence of metastasis. Metastatic tumors were found
on the liver, lymph node and adrenal glands of some of the PBS treated animals. B) Significant tumor regression was observed in more than 80%
of studied animals receiving BW-2 (P < 0.001).
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clinical toxicity in the BW-2 treated mice. Unsurprisingly,
mice treated with saporin toxin alone failed to demonstrate
inhibition of rapid local tumor growth, and this pattern
was also observed in mice treated with anti-HuD mAb or
PBS alone. All control mouse groups succumbed earlier
with overwhelming local tumor growth and massive distant
metastasis (Figure 4).
One of the major concerns in using anti-HuD immuno-
therapy in SCLC and NB is the potential development of
neurologic side effects. Due to the lack of an appropriate
animal model to aid in defining the precise relationship of
anti-HuD humoral immunity to the pathogenesis of pa-
raneoplastic encephalomyelitis or paraneoplastic sensory
neuropathy associated with HuD-positive malignances,
enthusiasm for the development of an anti-HuD antigenspecific immunotherapy for patients with SCLC has
remained low [11]. Similarly to DNA vaccination with
mouse HuD-antigen in a mouse model of neuroblastoma,
our intratumoral anti-HuD immunotoxin therapy inhib-
ited tumor growth without inducing clinically apparent
neurological symptoms in neuro-2a xenografted mice
[10]. Additionally, neuropathologic examination of the
brain, spinal cord and peripheral nerves in BW-2 treated
mice showed no evidence of pathology as judged by pres-
ence of inflammation or neuronal death.
Elevated infiltrating cytotoxic T cells have been asso-
ciated with favorable clinical outcomes in multiple
tumor types [13-15]. A vaccine with DNA coding for
Hu-protein in A/J mice has been reported to induce T
cell infiltration to tumor sites and reduce the size of
neuroblastoma (neuro-2a) tumors [10]. Our study in
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(tumor volume <600 mm3), substantial dendritic cells
(DCs) and T cells reside within the subcutaneous tumor
(data not shown). The proportion of infiltrating T cells
within the tumor progressively decreases as the tumor
grows, suggesting that the tumor-infiltrated immune cells
may play a vital role in inhibiting local and metastasized
tumor growth. The advantage of intratumoral immuno-
toxin therapy is that it selectively kills the targeted tumor
cells and causes minimal toxicity to the immune cells
within the tumor microenvironment, adjacent lymph
nodes, and systemically within the body [16,17]. Further-
more, the tumor antigens released from the lysed tumor
cells may be readily taken up and processed by local DCs
for cross-priming [17]. The amplified activation of local
anti-tumor T cells as well as T cells from other lymphoid
tissues may lead to eradication of the residual and meta-
static tumor cells as observed in our study.
The advent of cellular immunotherapies has further
propelled the use of monoclonal antibodies in the fight
against malignancies. Several anti-PD-1/anti-PD-L1 mAbs
are actively in clinical trials for treatment of a variety of
solid tumors including non-small cell lung cancer
(NSCLC) and melanoma [18-21]. Similarly, anti-CTLA-4
agents approved for treatment of melanoma have been
tested in advanced stage SCLC and NSCLC, though re-
sults for SCLC are thus far inconclusive [22,23]. The
highly successful chimeric ch14.18 mAb drastically im-
proved survival in high risk NB patients [24]. Targeting of
immunologic checkpoints has become a very popular and
promising approach to combating malignant disease.
However, this approach relies partially on antigen present-
ing cell dependent immunologic responses. Our demon-
strated approach may provide an excellent opportunity to
catch those who fall through the cracks of the immuno-
logic checkpoint therapies.Conclusions
Both SCLC and NB have very poor prognoses and
5-year survivals are less than 25% and 50% respectively
despite all available aggressive multimodality therapies.
Our study describing intratumoral immunotoxin ther-
apy in mouse models of SCLC and neuroblastoma
serves as a proof of concept and our findings may help
to maximize immunotherapeutic efficacy for a variety
of malignancies. In addition to the immunocompetent
mouse model of neuroblastoma described here, the
same strategy could reasonably be applied to other ani-
mal models of malignancies by switching to other
tumor antigen specific immunotoxin (antibody/toxin)
compounds. In the future, this new treatment may offer
clinicians a novel treatment option with significant
therapeutic potential for patients with solid tumors.Methods
Cell lines and reagents
Human SCLC (NCI-H69, DMS-79), human erythroleuke-
mia (K-562), mouse NB (neuro-2a) and mouse T lymph-
oma (BW5147) cell lines were purchased from the
American Type Culture Collection (ATCC; Rockville,
MD). Cells were maintained in growth medium supple-
mented with 10% fetal calf serum (FCS) as recommended
by the vendor. Saporin (SAP) and streptavidin-SAP were
purchased from Advanced Targeting Systems (Santiago,
CA) and stored at −80°C until use. Biotinylated and non-
biotinylated mouse anti-human HuD mAb 16A11 (IgG2b)
were purchased from Molecular Probes (Eugene, OR)
[8]. Immunotoxin BW-2 was prepared by premixing
biotinylated-16A11 mAb with streptavidin-SAP in
equal molar concentrations.
Western blot analysis
Neuro-2a (mouse neuroblastoma) cells were lysed and
total protein content was determined by measuring its
absorbance. Aliquots of 50 μg total protein from each
sample were subjected to SDS-polyacrylamide gel electro-
phoresis on a NuPAGE 4-12% Bis-Tris gel (Invitrogen,
Carlsbad, CA) followed by transfer to a nitrocellulose
membrane. The membrane was probed with primary
antibodies anti-HuC/D (6ug/mL, Molecular Probes,
Eugene, OR) followed by incubation with appropriate
HRP-conjugated secondary antibodies (GE healthcare,
Piscataway, NJ). The signal was visualized through the
use of the ECL Plus Western Blotting Detection Sys-
tem (GE Healthcare) and exposure to ECL Hyperfilm
(GE Healthcare). The membrane was stripped with
Re-Blot Plus Strong (Chemicon, Temecula, CA).
In vitro cell proliferation and cytotoxicity assays
Five ×104 tumor cells (NCI-H69, DMS-79, neuro-2a or
control K562 cells) in 100 ul of culture medium were
placed in each well of 96-well plates. Log dilutions
(0.005, 0.05, 0.5 and 5 μg/ml) of BW-2 were added to
the cell culture wells. Equivalent molar concentrations
of SAP, antibody alone as well as streptavidin alone
served as controls. The cells were incubated at 37°C, 5%
CO2 for 72 h. Cell viability was assayed using a modified
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide assay (Cell Titer 96 Cell Prolifer-
ation Assay kit, Promega Corp., Madison, WI) according
to the manufacturer’s instructions. Tunnel or trypan
blue staining was used on selected cell lines to confirm
the findings. Each assay was performed in triplicate.
Animals
Male athymic nude mice at age 5–6 weeks (NCRNUM)
were purchased from Taconic (Hudson, NY). Female A/J
mice at 6–8 weeks were purchased from Jackson laboratory
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in specific pathogen-free conditions and the studies were
conducted in accordance with the Animal Component of
Research Protocol guidelines at the VA Medical Center,
East Orange, NJ.
Tumor xenograft and allografts
The mouse model of human SCLC was established by
subcutaneous (s.c.) implantation of viable tumor cells
(1 × 107/100 μl PBS) into the flank of nude mice. Ani-
mals were monitored 5 days per week for tumor onset
and growth. Tumor size was measured using calipers
and final tumor volumes were calculated using a stand-
ard formula: length × width × height × 1/6 × π [9].
A mouse model of neuroblastoma was similarly
established by s.c. implantation of mouse neuro-2a cells
(1 × 107/100 μl PBS) into the flank of immunocompe-
tent female A/J mice at 6–8 weeks of age [10]. Tumor
size was measured 5 days per week as above. When pri-
mary tumors reached approximately 150-200 mm3,
mice (n = 5) received two intratumoral injections at
weekly intervals of either BW-2 at a dose of 1 mg/kg or
equivalent doses of PBS. Mice were monitored follow-
ing treatments 5 times per week for tumor growth and
general condition. Animals were sacrificed and perfused
with 4% paraformaldahyde when tumor burden became
too great.
Treatment protocol
When subcutaneous tumor nodules reached approximately
150–200 mm3 in size, the SCLC tumor xenografted nude
mice (n = 6) received treatment with one time intratumoral
immunotoxin at doses of 1 mg/kg, or equivalent doses of
pure 16A11 mAb alone, saporin toxin alone, or sham treat-
ment with saline. Mice were monitored 5 times per week
by measuring tumor size, assessing general condition,
weight changes, and presence of neurological symptoms
post treatment.
Minor modifications of the treatment protocol were
made for the NB allografted A/J mice (n = 5). When sub-
cutaneous NB tumor nodules reached a size of 150–200
mm3, mice received two intratumoral immunotoxin treat-
ments at weekly intervals. Mice receiving equivalent doses
of mAb (16A11) alone, saporin toxin alone, or sham
treatment with saline served as controls. Mice were
then monitored for tumor growth and general condi-
tion as described above.
Pathologic correlation
Local tumors and organs (lung, brain, liver, adrenal gland
and bone marrow) were collected for histopathologic studies
at serial time points post treatment. Standard hematoxylin/
eosin (H&E) and immunohistochemical reactions on the
tissue sections were performed with anti-HuD antibody(16A11) to determine the extent of tumor involvement.
Tissue sections of GFP-labeled neuro-2a tumors or organs
that exhibited metastasis were visualized directly under
fluorescent microscopy. To quantify the immune cell infil-
tration within the local s.c. tumor sites, immunochemical re-
actions on the frozen tumor tissue sections were conducted
with antisera (eBioscience, San Diego, CA) specific for
CD4, CD8, CD11c and Foxp3+ following manufac-
turer’s recommendations.
Statistics
Statistical analysis was performed using Instat software 3.0
(Graphpad Software, Philadelphia, PA). The composite
data was analyzed by the Kruskal-Wallis one-way analysis
of variance and the Mann–Whitney U test (two-tailed)
was used to determine the significance of intergroup
clinical response differences after treatment. A value of
P < 0.05 was considered significant.
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